These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22137622)

  • 21. Cyclosporine: update on pharmacology, analytical techniques and therapeutic monitoring.
    Santori L; Rastelli M; Arena B; Morleo MA
    Boll Chim Farm; 1997 Oct; 136(9):577-88. PubMed ID: 9440351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hair darkening after treatment with cyclosporin in a patient with psoriasis.
    Sadighha A; Zahed GM
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(10):1239-41. PubMed ID: 18331307
    [No Abstract]   [Full Text] [Related]  

  • 23. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.
    Lebwohl M; Ellis C; Gottlieb A; Koo J; Krueger G; Linden K; Shupack J; Weinstein G
    J Am Acad Dermatol; 1998 Sep; 39(3):464-75. PubMed ID: 9738783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.
    Kunynetz R; Carey W; Thomas R; Toth D; Trafford T; Vender R
    Eur J Dermatol; 2011; 21(1):89-94. PubMed ID: 21227890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis.
    Kress DW
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S126-8. PubMed ID: 16488325
    [No Abstract]   [Full Text] [Related]  

  • 26. An overview of the first decade of cyclosporine.
    Stiller CR
    Transplant Proc; 1996 Aug; 28(4):2005-12. PubMed ID: 8769139
    [No Abstract]   [Full Text] [Related]  

  • 27. Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept.
    Di Nuzzo S; Zanni M; De Panfilis G
    J Drugs Dermatol; 2007 Oct; 6(10):1046-7. PubMed ID: 17966184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psoriasis therapy after remission: the next step.
    Weinstein G
    Int J Dermatol; 1997 Dec; 36 Suppl 1():37-40. PubMed ID: 9466221
    [No Abstract]   [Full Text] [Related]  

  • 29. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice.
    Saurat JH; Guérin A; Yu AP; Latremouille-Viau D; Wu EQ; Gupta SR; Bao Y; Mulani PM
    Dermatology; 2010; 220(2):128-37. PubMed ID: 20130383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic management of psoriasis].
    Guilhou JJ
    Ann Dermatol Venereol; 1996; 123(4):276-9. PubMed ID: 8763756
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis.
    Umezawa Y; Ozawa A
    Int J Dermatol; 2007 Jul; 46(7):763-6. PubMed ID: 17614813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Systemic therapy of psoriasis].
    Altmeyer P; Nüchel C
    Dtsch Med Wochenschr; 1996 Dec; 121(51-52):1605-7. PubMed ID: 9011488
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclosporine resolves generalized pustular psoriasis of pregnancy.
    Kapoor R; Kapoor JR
    Arch Dermatol; 2006 Oct; 142(10):1373-5. PubMed ID: 17043209
    [No Abstract]   [Full Text] [Related]  

  • 35. Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia.
    Fozza C; Dore F; Bonfigli S; Podda L; Longinotti M
    Eur J Dermatol; 2005; 15(4):271-3. PubMed ID: 16048757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of calcineurin antagonists.
    Kapturczak MH; Meier-Kriesche HU; Kaplan B
    Transplant Proc; 2004 Mar; 36(2 Suppl):25S-32S. PubMed ID: 15041303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of the effects of betamethasone butyrate propionate, vitamin D3 derivatives, and cyclosporine on human lymphocyte-proliferation stimulated with a hemolytic streptococci-derived superantigen.
    Arai K; Uchiyama T; Okubo Y; Tsuboi R; Oka K; Hirano T
    Eur J Pharmacol; 2007 Oct; 571(2-3):222-30. PubMed ID: 17628528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressive agents in dermatology.
    Ho VC; Zloty DM
    Dermatol Clin; 1993 Jan; 11(1):73-85. PubMed ID: 8435920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis.
    Smith KJ; Skelton HG
    J Am Acad Dermatol; 1997 Apr; 36(4):656-8. PubMed ID: 9092768
    [No Abstract]   [Full Text] [Related]  

  • 40. Topical ophthalmic cyclosporine: pharmacology and clinical uses.
    Lipsky W
    Surv Ophthalmol; 2010; 55(2):189; author reply 189. PubMed ID: 20159231
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.